Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery

This publication has 22 references indexed in Scilit:

• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib
  Lung Cancer, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma
  Cancer, 2004
• Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2004
• Lung cancer * 9: Molecular biology of lung cancer: clinical implications
  Thorax, 2003
• The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’ ) is not related to the expression of EGFR or HER-2 or to K-ras gene status
  Lung Cancer, 2003
• Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non‐small cell lung cancer
  International Journal of Cancer, 2003
• Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
  Science, 1989